Biography for Damian Garde
Damian is an editor with Fierce's life sciences publications, writing for FierceMedicalDevices and FierceCRO. Prior to joining Fierce, he worked for Patch.com in Maryland, and The Albuquerque Journal and Weekly Alibi in Albuquerque, NM. Damian has a dog named Omar and considers himself the foremost Carmelo Anthony apologist in the greater Washington, DC, area. You can email him at firstname.lastname@example.org and follow @DamianFierce on Twitter.
Articles by Damian Garde
EuroPCR kicked off in Paris on Tuesday, bringing devicemakers from around the globe together to unveil data and angle for attention from the continent's interventional cardiovascular specialists. Here's a look at some early highlights from the conference.
Medtronic raked in $4.5 billion in revenue last quarter, riding a jump in international sales to 4% growth, but a spike in charges brought net profits down 2%.
Fresh off the launch its gene-expression cancer diagnostic, Seattle's NanoString is plotting an IPO worth up to $86.3 million, the company disclosed Monday.
The lengthy patent dispute between Medtronic and Boston Scientific will end in the nation's highest courtroom, as the Supreme Court has agreed to hear Medtronic's plea to avoid paying cardiac device royalties.
Medtronic snagged a CE mark for the Export Advance aspiration catheter, planning to launch the clot-removing device in Europe and other international markets.
In April, Abbott Laboratories announced it was yanking the FreeStyle InsuLinx blood glucose meters off the U.S. market, and now the FDA has assigned its most-serious Class I label to the effort, warning that the devices' malfunction could lead to serious injury or death.
Vascular Solutions is suing Boston Scientific, claiming the company's Guidezilla extension catheter infringes on its patents and asking a Minnesota court to hault the device's sale.
Thoratec scored the FDA's blessing to market a next-generation controller for the HeartMate II implant, giving the company a user-friendly face for its market-leading left ventricular assist device.
Quest Diagnostics is on a buying spree to grow its testing business, and now the company has signed a deal to buy the toxicology and clinical laboratory segment of health insurance giant Humana.
St Jude Medical has won European clearance for the Ilumien Optis PCI Optimization System, technology designed to help treat coronary artery disease by modeling vessels and guiding stent placement.